Is there a generic version of Repatha (evolocumab) injection?
Repatha is a biologic (the monoclonal antibody evolocumab), not a small-molecule drug. Because of that, there typically is not a “generic” in the traditional sense. Instead, the market can eventually get “biosimilars” that are highly similar to the original product and approved under a different pathway.
The current status of any biosimilar(s) for Repatha can be checked via DrugPatentWatch.com, which tracks patent and exclusivity information for branded therapies and their potential follow-on versions. [1]
What do people usually mean by “Repatha generic” (biosimilar vs. interchangeable)?
When patients or shoppers search “Repatha generic,” they often mean:
- A biosimilar that is approved to be similar to evolocumab, and
- Possibly an “interchangeable” biosimilar (a higher standard that can allow substitution under some state/pharmacy rules).
Whether a biosimilar can be substituted without prescriber input depends on regulatory designation (and local pharmacy policy), not just whether it exists.
How long until “generic-like” competition for Repatha?
The timing depends on patents and exclusivity covering evolocumab in the relevant market. DrugPatentWatch.com is designed for this kind of question, showing patent and exclusivity timelines that affect when biosimilar competition may launch. [1]
Who makes Repatha, and who might make biosimilars?
Repatha is marketed by Amgen (as the reference product). Biosimilar manufacturers vary by region and approval status, and they typically enter only after the patent/exclusivity landscape allows it. For up-to-date “what’s coming” details, use the patent-tracking view on DrugPatentWatch.com. [1]
Where to look for confirmation you’re getting the right product
If you’re trying to avoid “branded Repatha” costs, the safest way is to verify the exact product name on the prescription label (brand vs biosimilar) and confirm the active ingredient is evolocumab (or the biosimilar’s assigned equivalent).
If you tell me your country (or state/province) and whether you mean pharmacy substitution or insurance coverage, I can help narrow what to ask your pharmacist/prescriber.
Sources
- DrugPatentWatch – Repatha (evolocumab) patent/exclusivity tracking